Stock research
FBLG FibroBiologics, Inc. Common Stock
Healthcare • Biotechnology
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell,...…
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
3M change
-49.28%
Range high
$1.38
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in FBLG?
Price
Showing 3M history. Source: FMP historical price full.
- Prev Close
- $0.72
- Day High
- $0.74
- Day Low
- $0.68
- 52w High
- $13.00
- 52w Low
- $0.62
- Volume
- 105,406
- Avg Volume
- Beta
- 1.167
* TTM/most recent where available
Company
- Ticker
- FBLG
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- Peter O'Heeron
- Employees
- 15
- Website
- www.fibrobiologics.com
Key Metrics
- Market Cap
- 1.47M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).